S. 1339 118th Congress
Pharmacy Benefit Manager Reform Act
Latest action, Jun 22, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 113.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
4 cosponsors
Sponsored by Bernard Sanders (Independent). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
1 D · 3 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMAC ACTION, INC.
SCHOENING STRATEGIES, LLC
7 reports
AMERICAN BENEFITS COUNCIL
SPANGLER STRATEGIES LLC
7 reports
7 reports
7 reports
7 reports
7 reports
BRISTOL-MYERS SQUIBB
CROSSROADS STRATEGIES, LLC
7 reports
7 reports
7 reports
CROHN'S & COLITIS FOUNDATION
7 reports
7 reports
EDISON ELECTRIC INSTITUTE
MEHLMAN CONSULTING, INC.
7 reports
7 reports
All 25 of 167 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMAC ACTION, INC. | SCHOENING STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $20.1M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN BENEFITS COUNCIL | SPANGLER STRATEGIES LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 7 | $670K | Q4 2023 | Q3 2024 | yes | |
| ARTHRITIS FOUNDATION | 7 | $650K | Q4 2023 | Q3 2024 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 7 | $12.1M | Q4 2023 | Q3 2024 | yes | |
| BLUECROSS BLUESHIELD OF TENNESSEE | 7 | $1.8M | Q4 2023 | Q3 2024 | yes | |
| BOEING COMPANY | 7 | $22.5M | Q4 2023 | Q3 2024 | yes | |
| BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| CAMBIA HEALTH SOLUTIONS | 7 | $4.4M | Q4 2023 | Q3 2024 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 7 | $123.5M | Q4 2023 | Q3 2024 | yes | |
| CROHN'S & COLITIS FOUNDATION | 7 | $330K | Q4 2023 | Q3 2024 | yes | |
| CVS HEALTH (AND SUBSIDIARIES) | 7 | $14.0M | Q4 2023 | Q3 2024 | yes | |
| EDISON ELECTRIC INSTITUTE | MEHLMAN CONSULTING, INC. | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| ELEVANCE HEALTH, INC. | 7 | $10.3M | Q4 2023 | Q3 2024 | yes | |
| EMD SERONO INC | 7 | $4.7M | Q4 2023 | Q3 2024 | yes | |
| EPILEPSY FOUNDATION | 7 | $430K | Q4 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.2M | Q4 2023 | Q3 2024 | yes | |
| HIGHMARK INC | 7 | $1.3M | Q4 2023 | Q3 2024 | yes | |
| INDEPENDENT PHARMACY COOPERATIVE | 7 | $340K | Q4 2023 | Q3 2024 | yes | |
| INDEPENDENT PHARMACY COOPERATIVE | FORBES-TATE | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| INTRA-CELLULAR THERAPIES, INC. | 7 | $300K | Q4 2023 | Q3 2024 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 7 | $4.4M | Q4 2023 | Q3 2024 | yes | |
| MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY | 7 | $5.2M | Q4 2023 | Q3 2024 | yes | |
| MERCK & CO., INC. | CROSSROADS STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |